TET2 and acute myeloid leukemia: The ten-year OS rate for patients ≤60 years and with CEBPAbiallelic mutation was 81%. CEBPAbiallelic-mutated AML was associated with TET2 mutation in 34% of the patients, and the combination resulted in significantly worse OS, whereas it was associated with GATA2 (GATA binding protein 2, a transcription factor) mutation, found in 21% of CEBPAbiallelic-mutated AML, resulting in improved OS [89].